Clinical trial / 2021
Continued subcutaneous semaglutide led to continued weight loss compared to weight regain with placebo in adults with overweight or obesity.
Following a 20-week run-in with subcutaneous semaglutide resulting in a mean weight loss of 10.6%, 803 participants were randomized to 48 weeks of continued semaglutide (2.4 mg/week) or placebo, both with lifestyle intervention. From week 20 to 68, participants continuing semaglutide had a mean weight change of -7.9% compared to +6.9% with placebo (difference: -14.8 percentage points, P < .001). Continued semaglutide also led to greater improvements in waist circumference (-9.7 cm), systolic blood pressure (-3.9 mm Hg), and physical functioning scores. Gastrointestinal adverse events were reported in 49.1% of semaglutide participants versus 26.1% with placebo, though discontinuation rates due to adverse events were similar (2.4% vs 2.2%).
- Study type
- Randomized, double-blind, phase 3a withdrawal trial
- Who was studied
- 803 adults with overweight or obesity without diabetes who completed a 20-week semaglutide run-in
- What was measured
- Percent change in body weight from week 20 to week 68
THE PAPER
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D, STEP 4 Investigators. JAMA, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.